DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
IPI-549 is an investigational drug.
There have been 104 clinical trials for IPI-549. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2007.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, B-Cell, and Lymphoma, Large B-Cell, Diffuse. The leading clinical trial sponsors are Infinity Pharmaceuticals, Inc., Lymphoma Study Association, and Bristol-Myers Squibb.
Recent Clinical Trials for IPI-549
|Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have||National Cancer Institute (NCI)||Phase 3|
|A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1||Astex Pharmaceuticals, Inc.||Phase 2|
|A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1||Bristol-Myers Squibb||Phase 2|